NASDAQ:OM - Nasdaq - US6901451079 - Common Stock - Currency: USD
0.8754
-0.08 (-8.81%)
The current stock price of OM is 0.8754 USD. In the past month the price increased by 1.79%. In the past year, price decreased by -76.47%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. The company is headquartered in San Jose, California and currently employs 480 full-time employees. The company went IPO on 2020-09-15. The firm offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. The firm designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by virtually anyone. The Tablo system comprises components, which include Tablo Console, Tablo Cartridge and Tablo Data Ecosystem. Tablo Console is a compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and touchscreen interface with 3D animations. The company also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
OUTSET MEDICAL INC
3052 Orchard Drive
San Jose CALIFORNIA 95134 US
CEO: Leslie Trigg
Employees: 480
Company Website: https://outsetmedical.com/
Investor Relations: https://investors.outsetmedical.com/
Phone: 16692318200
The current stock price of OM is 0.8754 USD. The price decreased by -8.81% in the last trading session.
The exchange symbol of OUTSET MEDICAL INC is OM and it is listed on the Nasdaq exchange.
OM stock is listed on the Nasdaq exchange.
13 analysts have analysed OM and the average price target is 3.83 USD. This implies a price increase of 336.94% is expected in the next year compared to the current price of 0.8754. Check the OUTSET MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OUTSET MEDICAL INC (OM) has a market capitalization of 47.01M USD. This makes OM a Nano Cap stock.
OUTSET MEDICAL INC (OM) currently has 480 employees.
OUTSET MEDICAL INC (OM) has a support level at 0.8 and a resistance level at 0.91. Check the full technical report for a detailed analysis of OM support and resistance levels.
The Revenue of OUTSET MEDICAL INC (OM) is expected to grow by 7.67% in the next year. Check the estimates tab for more information on the OM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OM does not pay a dividend.
OUTSET MEDICAL INC (OM) will report earnings on 2025-05-06, after the market close.
OUTSET MEDICAL INC (OM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.8).
The outstanding short interest for OUTSET MEDICAL INC (OM) is 17.32% of its float. Check the ownership tab for more information on the OM short interest.
ChartMill assigns a technical rating of 2 / 10 to OM. When comparing the yearly performance of all stocks, OM is a bad performer in the overall market: 92.56% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to OM. While OM seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months OM reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS increased by 41.94% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -48.12% | ||
ROE | -294.71% | ||
Debt/Equity | 4.12 |
ChartMill assigns a Buy % Consensus number of 83% to OM. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 50.5% and a revenue growth 7.67% for OM